MedPath
HSA Approval

MOFECON-GR 180 GASTRO-RESISTANT TABLETS 180 MG

SIN16969P

MOFECON-GR 180 GASTRO-RESISTANT TABLETS 180 MG

MOFECON-GR 180 GASTRO-RESISTANT TABLETS 180 MG

March 8, 2024

GOLDPLUS UNIVERSAL PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGOLDPLUS UNIVERSAL PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, ENTERIC COATED

ORAL

Medical Information

L04AA06

mycophenolic acid

Manufacturer Information

GOLDPLUS UNIVERSAL PTE LTD

CONCORD BIOTECH LIMITED

Active Ingredients

Mycophenolate Sodium 192.35mg eqv Mycophenolic Acid

180mg

Mycophenolic acid

Documents

Package Inserts

1.4.3 Mofecon-GR Tablet (VIMOFxx-12) SIN_Nov23.pdf

Approved: March 8, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

MOFECON-GR 180 GASTRO-RESISTANT TABLETS 180 MG - HSA Approval | MedPath